Trial Outcomes & Findings for Photocil (Topical) for the Treatment of Psoriasis Vulgaris (NCT NCT01916629)
NCT ID: NCT01916629
Last Updated: 2016-03-10
Results Overview
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
12 participants
Primary outcome timeframe
90 days
Results posted on
2016-03-10
Participant Flow
Participant milestones
| Measure |
Photocil for Psoriasis
Active Drug - Photocil for Psoriasis
Photocil for Psoriasis: Photocil for Psoriasis
|
Placebo - Sunscreen (SPF 2)
Placebo - Sunscreen (SPF 2)
Placebo - Sunscreen (SPF 2): Placebo - Sunscreen (SPF 2)
|
|---|---|---|
|
Overall Study
STARTED
|
7
|
5
|
|
Overall Study
COMPLETED
|
7
|
5
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Photocil (Topical) for the Treatment of Psoriasis Vulgaris
Baseline characteristics by cohort
| Measure |
Photocil for Psoriasis
n=7 Participants
Active Drug - Photocil for Psoriasis
Photocil for Psoriasis: Photocil for Psoriasis
|
Placebo - Sunscreen (SPF 2)
n=5 Participants
Placebo - Sunscreen (SPF 2)
Placebo - Sunscreen (SPF 2): Placebo - Sunscreen (SPF 2)
|
Total
n=12 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
45 years
STANDARD_DEVIATION 9.7 • n=93 Participants
|
35 years
STANDARD_DEVIATION 14 • n=4 Participants
|
41 years
STANDARD_DEVIATION 12 • n=27 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
3 Participants
n=27 Participants
|
|
Sex: Female, Male
Male
|
5 Participants
n=93 Participants
|
4 Participants
n=4 Participants
|
9 Participants
n=27 Participants
|
|
Region of Enrollment
United States
|
7 participants
n=93 Participants
|
5 participants
n=4 Participants
|
12 participants
n=27 Participants
|
PRIMARY outcome
Timeframe: 90 daysOutcome measures
| Measure |
Photocil for Psoriasis
n=7 Participants
Active Drug - Photocil for Psoriasis
Photocil for Psoriasis: Photocil for Psoriasis
|
Placebo - Sunscreen (SPF 2)
n=5 Participants
Placebo - Sunscreen (SPF 2)
Placebo - Sunscreen (SPF 2): Placebo - Sunscreen (SPF 2)
|
|---|---|---|
|
Percent Lesion Clearance
|
75.7 Percent Clearance
Standard Deviation 23.7
|
8 Percent Clearance
Standard Deviation 8.3
|
Adverse Events
Photocil for Psoriasis
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Placebo - Sunscreen (SPF 2)
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60